Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;3(3):66-75.
doi: 10.1177/2051013615593891.

Recent advances in the development of vaccines for tuberculosis

Mohamed Jawed Ahsan  1
Affiliations
Review

Recent advances in the development of vaccines for tuberculosis

Mohamed Jawed Ahsan. Ther Adv Vaccines. 2015 May.

Abstract

Tuberculosis (Tb) continues to be a dreadful infection worldwide with nearly 1.5 million deaths in 2013. Furthermore multi/extensively drug-resistant Tb (MDR/XDR-Tb) worsens the condition. Recently approved anti-Tb drugs (bedaquiline and delamanid) have the potential to induce arrhythmia and are recommended in patients with MDR-Tb when other alternatives fail. The goal of elimination of Tb by 2050 will not be achieved without an effective new vaccine. The recent advancement in the development of Tb vaccines is the keen focus of this review. To date, Bacille Calmette Guerin (BCG) is the only licensed Tb vaccine in use, however its efficacy in pulmonary Tb is variable in adolescents and adults. There are nearly 15 vaccine candidates in various phases of clinical trials, includes five protein or adjuvant vaccines, four viral-vectored vaccines, three mycobacterial whole cell or extract vaccines, and one each of the recombinant live and the attenuated Mycobacterium tuberculosis (Mtb) vaccine.

Keywords: Bacille Calmette Guerin; clinical trials; review; tuberculosis vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author reports no financial conflicts of interest.

Figures

Figure 1.
Figure 1.
Tuberculosis vaccines in various phases of clinical trials.
See this image and copyright information in PMC

References

    1. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. (2010) The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 181: 1407–1417. - PMC - PubMed
    1. Ahsan M., Garg S., Vashishtha B., Sharma P. (2013) Tuberculosis vaccines: hopes and hurdles. Infect Disord Drug Targets 13: 318–321. - PubMed
    1. Arbues A., Aguilo J., Gonzalo-Asensio J., Marinova D., Uranga S., Puentes E., et al. (2013) Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 31: 4867–4873. - PubMed
    1. Billeskov R., Elvang T., Andersen P., Dietrich J. (2012) The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-Mycobacterial protective immunity. PLoS One 7: e39909. - PMC - PubMed
    1. Cardona P., Amat I. (2006) Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection. Arch Bronconeumol 42: 25–32. - PubMed

LinkOut - more resources